<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160706028815N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-04-29</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Crocin in treatment of breast cancer</public_title>
      <acronym></acronym>
      <scientific_title>Assessment of the effectiveness of addition of Crocin to doxorubicin containing chemotherapy regimen on survival of breast cancer patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30791</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with block randomization (1:1) will be allocated to treatment or placebo groups. First patients will be entered into one group based on sealed envelops and second patient will entered another group. Patients will be allocated to groups consecutively, Blinding description: This is a double blind study and the responsible physician for assessment of the clinical symptoms and imaging and patients are blind.  An individual outside the study team will take responsibility for randomization to crocin and placebo.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Malignant neoplasm of breast.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The patients will be requested to take two crocin tablets daily for four months (each tablet contain 15 milligram crocin). The crocin tabletes will be produced in the pharmacy faculty of Mashhad University of Medical Sciences from saffron. Although, the doxorubicin-containing chemotherapy regimen -using standard chemotherapy protocols in treatment of breast cancer- will be selected and will be calculated based on body surface area and will be prescribed every two-three weeks. Intervention 2: Control group: The patients will be requested to take two placebo tablets daily for four months. The crocin tabletes will be produced in the pharmacy faculty of Mashhad University of Medical Sciences. Although, the doxorubicin-containing chemotherapy regimen -using standard chemotherapy protocols in treatment of breast cancer- will be selected and will be calculated based on body surface area and will be prescribed every two-three weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Mansooreh Dehghani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Koohsangi Ave.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>917661377</zip>
        <telephone>+98 51 3842 6083</telephone>
        <email>DehghaniM951@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Roham Salek</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Koohsangi Ave.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>917661377</zip>
        <telephone>+98 51 3842 6083</telephone>
        <email>DehghaniM951@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Newly diagnosed invasive breast cancer
The Karnofsky Performance Scale Index equal to or more than 70%
doxorubicin containing chemotherapy regimen
Unilateral breast cancer
Age between 18 to 70 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>chronic liver failure
chronic kidney failure
chronic heart failure
previous history of hematologic malignancies
History of taking Psychiatric drugs
Warfarin usage
Bipolar mood disorder
Evidence of metastasis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The patients will be requested to take two crocin tablets daily for four months (each tablet contain 15 milligram crocin). The crocin tabletes will be produced in the pharmacy faculty of Mashhad University of Medical Sciences from saffron. Although, the doxorubicin-containing chemotherapy regimen -using standard chemotherapy protocols in treatment of breast cancer- will be selected and will be calculated based on body surface area and will be prescribed every two-three weeks.</i_keyword>
      <i_keyword>Control group: The patients will be requested to take two placebo tablets daily for four months. The crocin tabletes will be produced in the pharmacy faculty of Mashhad University of Medical Sciences. Although, the doxorubicin-containing chemotherapy regimen -using standard chemotherapy protocols in treatment of breast cancer- will be selected and will be calculated based on body surface area and will be prescribed every two-three weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Overall Survival. Timepoint: Every 3 months in the first year, every 4-6 months in the second year, every 6 months in third to fifth years and then annually. Method of measurement: visit.</prim_outcome>
      <prim_outcome>Progression-free Survival. Timepoint: Every 3 months in the first year, every 4-6 months in the second year, every 6 months in third to fifth years and then annually. Method of measurement: Visit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anemia. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: laboratory assessment of Complete blood count.</sec_outcome>
      <sec_outcome>Neutropenia. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: laboratory assessment of Complete blood count.</sec_outcome>
      <sec_outcome>Thrombocytopenia. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: laboratory assessment of Complete blood count.</sec_outcome>
      <sec_outcome>Alopecia. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: physical examination.</sec_outcome>
      <sec_outcome>Nausea. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: history taking.</sec_outcome>
      <sec_outcome>Vomiting. Timepoint: Before each session of chemotherapy every two to three weeks. Method of measurement: history taking.</sec_outcome>
      <sec_outcome>Depression. Timepoint: In the first visit and then every four months. Method of measurement: Beck's Depression Inventory.</sec_outcome>
      <sec_outcome>Anxiety. Timepoint: In the first visit and then every four months. Method of measurement: The Beck Anxiety Inventory.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-11-01</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Daneshgah Ave. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
